Cost-Effectiveness of Low-Field Intraoperative Magnetic Resonance in Glioma Surgery.

Karnofsky performance status cost-effectiveness glioma incremental cost-effective ratio intraoperative magnetic resonance progression-free survival (PFS) technology assessment

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 23 07 2020
accepted: 09 10 2020
entrez: 23 11 2020
pubmed: 24 11 2020
medline: 24 11 2020
Statut: epublish

Résumé

Low-field intraoperative magnetic resonance (LF-iMR) has demonstrated a slight increase in the extent of resection of intra-axial tumors while preserving patient`s neurological outcomes. However, whether this improvement is cost-effective or not is still matter of controversy. In this clinical investigation we sought to evaluate the cost-effectiveness of the implementation of a LF-iMR in glioma surgery. Patients undergoing LF-iMR guided glioma surgery with gross total resection (GTR) intention were prospectively collected and compared to an historical cohort operated without this technology. Socio-demographic and clinical variables (pre and postoperative KPS; histopathological classification; Extent of resection; postoperative complications; need of re-intervention within the first year and 1-year postoperative survival) were collected and analyzed. Effectiveness variables were assessed in both groups: Postoperative Karnofsky performance status scale (pKPS); overall survival (OS); Progression-free survival (PFS); and a variable accounting for the number of patients with a greater than subtotal resection and same or higher postoperative KPS (R-KPS). All preoperative, procedural and postoperative costs linked to the treatment were considered for the cost-effectiveness analysis (diagnostic procedures, prosthesis, operating time, hospitalization, consumables, LF-iMR device, etc). Deterministic and probabilistic simulations were conducted to evaluate the consistency of our analysis. 50 patients were operated with LF-iMR assistance, while 146 belonged to the control group. GTR rate, pKPS, R-KPS, PFS, and 1-year OS were respectively 13,8% (not significative), 7 points (p < 0.05), 17% (p < 0.05), 38 days (p < 0.05), and 3.7% (not significative) higher in the intervention group. Cost-effectiveness analysis showed a mean incremental cost per patient of 789 € in the intervention group. Incremental cost-effectiveness ratios were 111 € per additional point of pKPS, 21 € per additional day free of progression, and 46 € per additional percentage point of R-KPS. Glioma patients operated under LF-iMR guidance experience a better functional outcome, higher resection rates, less complications, better PFS rates but similar life expectancy compared to conventional techniques. In terms of efficiency, LF-iMR is very close to be a dominant technology in terms of R-KPS, PFS and pKPS.

Identifiants

pubmed: 33224884
doi: 10.3389/fonc.2020.586679
pmc: PMC7667256
doi:

Types de publication

Journal Article

Langues

eng

Pagination

586679

Informations de copyright

Copyright © 2020 Garcia-Garcia, García-Lorenzo, Ramos, Gonzalez-Sanchez, Culebras, Restovic, Alcover, Pons, Torales, Reyes, Sampietro-Colom and Enseñat.

Références

Clin Neurol Neurosurg. 2018 Jul;170:165-169
pubmed: 29803727
World Neurosurg X. 2019 Feb 20;3:100022
pubmed: 31225516
J Neurooncol. 2015 Sep;124(3):345-56
pubmed: 26297044
BMJ. 2008 Sep 29;337:a1204
pubmed: 18824485
Lancet. 2014 Feb 15;383(9917):614-21
pubmed: 24268105
PLoS One. 2016 Dec 22;11(12):e0168264
pubmed: 28005980
Eur J Cancer. 2019 Jan;107:15-27
pubmed: 30529899
Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6
pubmed: 18496181
CNS Oncol. 2017 Oct;6(4):307-313
pubmed: 28990795
Health Econ. 2018 Apr;27(4):746-761
pubmed: 29282798
World Neurosurg. 2017 Jun;102:102-110
pubmed: 28254595
J Magn Reson Imaging. 2011 Nov;34(5):1022-30
pubmed: 22002753
Cochrane Database Syst Rev. 2018 Jan 22;1:CD012788
pubmed: 29355914
J Neurosurg Sci. 2019 Dec;63(6):625-632
pubmed: 31355623
Cochrane Database Syst Rev. 2014 Jan 28;(1):CD009685
pubmed: 24474579
Nat Rev Clin Oncol. 2018 Feb;15(2):112-125
pubmed: 29158591
J Neurosurg. 2017 Oct;127(4):857-866
pubmed: 27885950
Surg Neurol Int. 2014 May 15;5:70
pubmed: 24991473
Neurotherapeutics. 2009 Jul;6(3):478-86
pubmed: 19560738
J Neurosurg Pediatr. 2018 Nov 30;23(3):308-316
pubmed: 30544362
Neuro Oncol. 2012 Sep;14 Suppl 4:iv55-64
pubmed: 23095831
Int J Surg. 2019 Mar;63:90-97
pubmed: 30742934
Neurosurgery. 2006 Jul;59(1):105-14; discussion 105-14
pubmed: 16823306
Methods Mol Biol. 2009;472:323-42
pubmed: 19107440
CNS Oncol. 2017 Jan;6(1):29-43
pubmed: 27628854
Neurocirugia (Astur). 2017 May - Jun;28(3):103-110
pubmed: 27751711
Front Neurol. 2012 Oct 18;3:140
pubmed: 23087667
Neurosurgery. 2014 Aug;61 Suppl 1:145-54
pubmed: 25032543
Handb Clin Neurol. 2012;105:437-50
pubmed: 22230511
J Clin Oncol. 2009 Mar 1;27(7):1082-6
pubmed: 19139429
Lancet Oncol. 2011 Oct;12(11):997-1003
pubmed: 21868284
World Neurosurg. 2018 Apr;112:e269-e277
pubmed: 29337167
Brain Sci. 2017 Dec 25;8(1):
pubmed: 29295569
Eur J Neurol. 2010 Sep;17(9):1124-33
pubmed: 20718851
Int J Technol Assess Health Care. 2013 Apr;29(2):117-22
pubmed: 23587340
Acta Neurochir Suppl. 2003;85:55-63
pubmed: 12570138
Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76
pubmed: 18425006
Acta Neurochir Suppl. 2011;109:49-53
pubmed: 20960320
World Neurosurg. 2019 Oct;130:e206-e212
pubmed: 31203073
Curr Treat Options Neurol. 2014 Apr;16(4):284
pubmed: 24595756
Lancet. 2009 Sep 26;374(9695):1105-12
pubmed: 19782876

Auteurs

Sergio Garcia-Garcia (S)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Borja García-Lorenzo (B)

Assessment of Innovations and New Technologies Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain.

Pedro Roldan Ramos (PR)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Jose Juan Gonzalez-Sanchez (JJ)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Diego Culebras (D)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Gabriela Restovic (G)

Assessment of Innovations and New Technologies Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain.

Estanis Alcover (E)

Economic and Financial Management Department, Hospital Clinic, Barcelona, Spain.

Imma Pons (I)

Economic and Financial Management Department, Hospital Clinic, Barcelona, Spain.

Jorge Torales (J)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Luis Reyes (L)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Laura Sampietro-Colom (L)

Assessment of Innovations and New Technologies Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain.

Joaquim Enseñat (J)

Department of Neurological Surgery, Hospital Clinic, Barcelona, Spain.

Classifications MeSH